Jennifer R. Brown, MD, PhD is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School in Boston, Massachusetts. Her particular interests include the development of novel targeted therapeutics for CLL, as well as the genomics of CLL. She has been instrumental in the clinical development of both idelalisib and ibrutinib, leading to their regulatory approvals in CLL. In the area of genomics she has been instrumental in the description of the somatic mutation profile of CLL, and is now particularly interested in the implementation of genomic technology in the clinic, including for prognosis and targeted therapy. She also has a longstanding research interest and focus on the inherited predisposition to CLL. To date she has published over 150 papers in the scientific literature, predominantly in CLL. She is an active member of the CLL Research Consortium and serves on the Alliance Leukemia and Leukemia Correlative Science Committees as well as the NIH Cancer Biomarkers Study Section. Dr Brown's attendance is kindly supported by Astra Zeneca.

Philip Thompson is an Associate Professor of Haematology in the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia and a Clinical Haematologist at The Peter MacCallum Cancer Centre and Royal Melbourne Hospitals in Melbourne, Australia. After graduating from The University of Melbourne and completing Residency and Haematology training in Melbourne, he undertook a Leukemia Fellowship at M.D. Anderson Cancer Center in Houston, before joining the Faculty at M.D. Anderson from 2015-2023. There, he described the functional cure of patients with low-risk CLL after FCR chemoimmunotherapy and developed research interests in the treatment of high-risk CLL and Richter Transformation, and the development MRD-adapted treatment approaches. Dr. Thompson has led several clinical trials in these areas and has authored or co-authored more than 100 papers.

Dr Xavier Badoux is a clinical haematologist with appointments at St George public and St George Private hospitals. He is a conjoint lecturer at the University of NSW. Xavier has a strong research interest in Chronic Lymphocytic Leukaemia (CLL) and lymphoproliferative diseases. He graduated from Harvard University, Massachusetts, followed by his medical degree from the University of Sydney and obtained dual fellowships under the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA). After his speciality training, Xavier completed a clinical fellowship in 2011 at the Leukemia department at MD Anderson Cancer Center in Houston, Texas. He pursued a research interest in novel therapeutic mechanisms in CLL, investigating the immunological changes occurring with immunomodulatory therapy. Since his return to Australia, Xavier maintains a strong interest in lymphoma and leukaemia research. Furthermore, he is the principal investigator in a number of international clinical trials in chronic Lymphocytic leukaemia and lymphoma, exploring the benefits of novel targeted therapies in the treatment of these diseases. He is the author of a number of peer-reviewed original research in high-impact journals.